Additionally, inhibiting KMO activity during AKI appears to be a more specific and safe solution than targeting IDO, making it a valuable therapeutic approach to protect against AKI development caused by acute inflammation (Figure 3) [160,163]. This evidence concerns the gene IDO1 and acute kidney injury.